News

With so many mobile vendors rushing to market diabetes applications and devices, will the lessons they learn translate to better mHealth products across the board?

23andme has been ordered to stop marketing its $99 DNA testing kits until its medical claims can be verified and the device receives FDA clearance.

The fastest demographic coming online has shown great interest in using mobile technologies, but most are still finding a lack of available options for doing so.

mHealth tools and services play an important role in the nation's migration to a patient-centered healthcare system. After all, what better way to empower a consumer than to give him/her access to healthcare records and healthcare providers through his or her smartphone or tablet? This infographic from the IMS Institute for Healthcare Informatics illustrates just how far we've come.